• Je něco špatně v tomto záznamu ?

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

B. Weinbergerová, J. Mayer, T. Kabut, WR. Sperr, J. Števková, A. Jonášová, M. Čerňan, S. Herndlhofer, I. Oravcová, J. Šrámek, J. Novák, R. Štěpánová, T. Szotkowski, L. Drgoňa, P. Žák, P. Valent

. 2024 ; 205 (5) : 1746-1750. [pub] 20240723

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003718

Grantová podpora
LX22NPO5102 National Institute for Cancer Research Project
EuropeanUnion-Next Generation EU
Czech Leukemia Study Group for Life (CELL)

Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003718
003      
CZ-PrNML
005      
20250206104635.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.19670 $2 doi
035    __
$a (PubMed)39044120
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Weinbergerová, Barbora $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000164602471
245    10
$a Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis / $c B. Weinbergerová, J. Mayer, T. Kabut, WR. Sperr, J. Števková, A. Jonášová, M. Čerňan, S. Herndlhofer, I. Oravcová, J. Šrámek, J. Novák, R. Štěpánová, T. Szotkowski, L. Drgoňa, P. Žák, P. Valent
520    9_
$a Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x farmakoterapie $x komplikace $7 D015470
650    12
$a bicyklické sloučeniny heterocyklické $x aplikace a dávkování $x terapeutické užití $7 D019086
650    12
$a azacytidin $x aplikace a dávkování $x terapeutické užití $7 D001374
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a sulfonamidy $x aplikace a dávkování $x terapeutické užití $7 D013449
650    12
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $x aplikace a dávkování $7 D000971
650    12
$a antifungální látky $x terapeutické užití $x aplikace a dávkování $7 D000935
650    12
$a mykózy $x prevence a kontrola $x etiologie $7 D009181
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Mayer, Jiří $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Kabut, Tomáš $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Sperr, Wolfgang R $u Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
700    1_
$a Števková, Jana $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Jonášová, Anna $u Medical Department, Hematology, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Čerňan, Martin $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Herndlhofer, Susanne $u Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
700    1_
$a Oravcová, Iveta $u Department of Oncohematology, Comenius University and National Cancer Institute, Bratislava, Slovakia
700    1_
$a Šrámek, Jiří $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Novák, Jan $u Department of Haematology, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Štěpánová, Radka $u Faculty of Medicine, Center of Excellence CREATIC, Masaryk University, Brno, Czech Republic
700    1_
$a Szotkowski, Tomáš $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Drgoňa, Luboš $u Department of Oncohematology, Comenius University and National Cancer Institute, Bratislava, Slovakia
700    1_
$a Žák, Pavel $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Valent, Peter $u Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 205, č. 5 (2024), s. 1746-1750
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39044120 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104631 $b ABA008
999    __
$a ok $b bmc $g 2263468 $s 1239725
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 205 $c 5 $d 1746-1750 $e 20240723 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
GRA    __
$a LX22NPO5102 $p National Institute for Cancer Research Project
GRA    __
$p EuropeanUnion-Next Generation EU
GRA    __
$p Czech Leukemia Study Group for Life (CELL)
LZP    __
$a Pubmed-20250121
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace